Newbridge Financial Services Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Newbridge Financial Services Group’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.51M	Sell	2,998 -63	-2%	-$33.3K	0.17%	106
2026 Q2	$1.64M	Sell	3,061 -417	-12%	-$214K	0.2%	97
2026 Q1	$1.82M	Sell	3,478 -70	-2%	-$33.4K	0.3%	72
2025 Q4	$2.07M	Sell	3,548 -94	-3%	-$48K	0.32%	67
2025 Q3	$1.67M	Buy	3,642 +66	+2%	+$24.6K	0.25%	81
2025 Q2	$1.08M	Sell	3,576 -952	-21%	-$284K	0.18%	98
2025 Q1	$1.5M	Buy	4,528 +325	+8%	+$107K	0.36%	62
2024 Q4	$1.3M	Buy	+4,203	New	+$1.18M	0.33%	67
2024 Q3	–	Sell	-5,894	Closed	-$1.65M	–	928
2024 Q2	$1.65M	Sell	5,894 -5,139	-47%	-$1.22M	0.62%	36
2024 Q1	$2.95M	Buy	+11,033	New	+$2.6M	1.29%	10

Other funds holding MDGL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Newbridge Financial Services Group's MDGL Position: Q3 2026 in Review

Newbridge Financial Services Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 2.1% in Q3 2026, selling an estimated $33.3K and leaving 2,998 shares worth $1.51M. The position accounts for 0.17% of the portfolio, ranked #106.

Newbridge Financial Services Group first reported a position in MDGL in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.95M in Q1 2024. 226 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

Newbridge Financial Services Group held 2,998 shares of Madrigal Pharmaceuticals worth $1.51M as of Q3 2026.
Newbridge Financial Services Group sold 63 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $33.3K.
Madrigal Pharmaceuticals made up 0.17% of Newbridge Financial Services Group's portfolio in Q3 2026, its #106 holding.
Newbridge Financial Services Group first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Newbridge Financial Services Group's Madrigal Pharmaceuticals position peaked at $2.95M in Q1 2024.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Newbridge Financial Services Group's 13F filing for Q3 2026, filed 15 Oct 2026.